Posted by Michael Wonder on 15 Jul 2021
Another month, another terminated appraisal of a cancer medicine
14 July 2021 - This time it is a medicine for adults and children with acute lymphoblastic leukaemia.
NICE is unable to make a recommendation on the use of dasatinib monohydrate (Sprycel) for Philadelphia chromosome positive acute lymphoblastic leukaemia in children and adults because BMS did not provide an evidence submission.
NICE will review this decision if BMS decides to make a submission.
